TY - JOUR T1 - Duovent – is logic enough? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 3 LP - 4 DO - 10.1136/dtb.23.1.3 VL - 23 IS - 1 A2 - , Y1 - 1985/01/14 UR - http://dtb.bmj.com/content/23/1/3.abstract N2 - Duovent (WB Pharmaceuticals) is a fixed-dose combination aerosol containing fenoterol (100 μg per puff) - a β2-adrenoceptor stimulant, and ipratropium (40 μg per puff) - an atropine-like agent. It is marketed for the treatment of bronchoconstriction in patients with asthma, chronic bronchitis or emphysema. The manufacturer claims that it is a ‘logical combination’ offering ‘first line treatment’, but the British National Formulary1 states that compound bronchodilators (including Duovent) ‘have no place in the management of patients with airways obstruction’. ER -